- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01954030
Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure
A Phase 1/2 Trial of Carboxyamidotriazole Orotate (CTO) Alone or in Combination With Bevacizumab for Adult Patients With Recurrent Malignant Glioma Post-Bevacizumab Failure
The primary objectives of the study are to determine the maximum tolerated dose (MTD) of Carboxyamidotriazole Orotate (CTO) when combined with standard dosing of bevacizumab among patients with recurrent malignant glioma (WHO grade III or IV) that have previously failed bevacizumab (Phase 1); to determine the activity of CTO alone in bevacizumab-failure WHO grade IV malignant glioma patients (Phase 2, Arm 1); to determine the activity of CTO plus bevacizumab in bevacizumab-failure WHO grade IV malignant glioma patients (Phase 2, Arm 2).
This study was terminated early due to funding issues. At the time of termination, the study was still in Phase 1 and no MTD for the combination of CTO and bevacizumab had been determined for this population. Phase 2 will not proceed.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
In Phase 1 of the study, we will conduct a dose-escalation study of the combination of CTO with the standard dosing of bevacizumab among patients with recurrent malignant glioma (WHO Grade III or IV) that have previously failed bevacizumab. All patients will have also received standard treatment with radiation therapy and temozolomide prior to enrollment on study.
The Phase 2 portion of this study will investigate two novel treatment regimens sequentially. Each regimen will include 25 patients with recurrent WHO grade IV malignant glioma who have been treated in the past with standard radiation therapy, temozolomide, and bevacizumab. All patients must have failed therapy while on bevacizumab. Subjects in the first treatment regimen will receive CTO alone and subjects in the second treatment regimen will receive the combination of CTO and bevacizumab together.
Note: This study was terminated early due to funding issues. At the time of termination, the study was still in Phase 1 and no MTD for the combination of CTO and bevacizumab had been determined for this population. Phase 2 will not proceed.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
North Carolina
-
Durham, North Carolina, Stati Uniti, 27710
- The Preston Robert Tisch Brain Tumor Center at Duke
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Phase 1 portion: Patients must have recurrent histologically confirmed diagnosis of World Health Organization (WHO) grade III or IV malignant glioma with no more than 3 prior progressions
- Phase 2 portion: Patients must have recurrent histologically confirmed diagnosis of WHO grade IV malignant glioma (glioblastoma or gliosarcoma) with no more than 3 prior progressions.
- Must have had a least 1 prior progression on a bevacizumab-containing regimen
- Age greater than or equal to 18 years
- Karnofsky ≥ 70%
- Bi-dimensionally measurable disease, as assessed by magnetic resonance imaging based on The Revised Assessment in Neuro-Oncology (RANO) criteria
- Absolute neutrophil count (ANC) ≥1000 cells/µl, Platelets ≥ 100,000 cells/µl (without transfusion within 14 days before enrollment)
- Adequate renal function as indicated by the following: Serum creatinine < 1.25 times upper limit of normal (ULN) or calculated creatinine clearance ≥ 50 ml/min; Urine dipstick for proteinuria < 2+ unless a 24-hour urine protein <1 g of protein is demonstrated
- Prothrombin time (PT) ≤ 1.5 x ULN and activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN within 14 days prior to first study treatment for patients not receiving anti-coagulation. The use of full-dose oral or parenteral anticoagulants is permitted as long as the PT or aPTT is within therapeutic limits (according to the medical standard of the enrolling institution) and the patient has been on a stable dose of anticoagulants for at least two weeks prior to the first study treatment.
- For patients on corticosteroids, they must be on a stable dose for 7 days prior to anticipated start of study drug, and the dose should not be escalated over entry dose level, if clinically possible
- Signed informed consent approved by the Institutional Review Board
- No evidence of > grade 1 active central nervous system (CNS) hemorrhage on the baseline magnetic resonance imaging (MRI) or computed tomography (CT) scan
- Female patients must not be pregnant or breast-feeding. Female patients of childbearing potential (defined as < 2 years after last menstruation or not surgically sterile) must use a highly effective contraceptive method (allowed methods of birth control, [i.e. with a failure rate of < 1% per year] are implants, injectables, combined oral contraceptives, intra-uterine device (IUD) (only hormonal), sexual abstinence or vasectomized partner) during the trial and for a period of > 6 months following the last administration of trial drug(s). Female patients with an intact uterus (unless amenorrhea for the last 24 months) must have a negative serum pregnancy test within 48 hours prior to first study treatment.
- Fertile male patients must agree to use a highly effective contraceptive method (allowed methods of birth control [i.e. with a failure rate of < 1% per year] include a female partner using implants, injectables, combined oral contraceptives, IUDs [only hormonal], sexual abstinence or prior vasectomy) during the trial and for a period of > 6 months following the last administration of trial drugs.
Exclusion Criteria:
- Pregnancy or breast-feeding
- Co-medication that may interfere with study results, for example, immuno-suppressive agents other than corticosteroids
- Active infection requiring intravenous (IV) antibiotics within 7 days before enrollment
- Prior, unrelated malignancy requiring current active treatment with the exception of cervical carcinoma in situ and adequately treated basal cell or squamous cell carcinoma of the skin
- Taking cytochrome P450 3A4 (CYP3A4) inducers and moderate or strong inhibitors (Note: Corticosteroids are allowed, as long as patients have been on a stable dose for 7 days prior to anticipated start of study drug, and the dose should not be escalated over entry dose level, if clinically possible)
- Less than 12 weeks from radiation therapy, unless progressive disease outside of the radiation field or progression on 2 consecutive scans or histopathologic confirmation
- Treated with immunotherapeutic agents or vaccines within 4 weeks before enrollment, unless the patient has recovered from the expected toxic effects of such therapy
- Treated with alkylating agents within 4 weeks before enrollment or treated with daily or metronomic chemotherapy within 1 week before enrollment, unless the patient has recovered from the expected toxic effects of such therapy
- Prior chemotherapy (non-alkylating agents) within 2 weeks before enrollment, unless the patient has recovered from the expected toxic effects of such therapy
- Current, recent (within 4 weeks of the first infusion of this study) use of an experimental drug, unless the patient has recovered from the expected toxic effects of study therapy
Vascular endothelial growth factor (VEGF) Inhibitor-Specific Exclusion Criteria are:
- Inadequately controlled hypertension (defined as systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 100 mmHg) within 28 days of first study treatment
- Prior history of hypertensive crisis, hypertensive encephalopathy, reverse posterior leukoencephalopathy syndrome (RPLS)
- Prior history of gastrointestinal perforation or abscess
- Clinically significant (active) cardiovascular disease, for example cerebrovascular accidents ≤ 6 months prior to study enrollment, myocardial infarction ≤ 6 months prior to study enrollment, unstable angina, New York Heart Association (NYHA) Grade 2 or greater congestive heart failure (CHF), or serious cardiac arrhythmia uncontrolled by medication or potentially interfering with protocol treatment
- History or evidence upon physical/neurological examination of central nervous system disease (for example, seizures) unrelated to cancer unless adequately controlled by medication or potentially interfering with protocol treatment
- Significant vascular disease (for example, aortic aneurysm requiring surgical repair or recent arterial thrombosis) within 6 months prior to start of study treatment
- History of pulmonary hemorrhage/hemoptysis ≥ grade 2 (defined as ≥ 2.5 mL bright red blood per episode) within 1 month of first study treatment
- History or evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding (in the absence of therapeutic anticoagulation)
- Current or recent (within 10 days of study enrollment) use of aspirin (> 325 mg/day), clopidogrel (> 75 mg/day) or equivalent. Prophylactic or therapeutic low molecular weight heparin (LMWH) is allowed.
- Surgical procedure (including open biopsy, surgical resection, wound revision, or any other major surgery involving entry into a body cavity) or significant traumatic injury within 28 days prior to first study treatment, or anticipation of need for major surgical procedure during the course of the study
- Minor surgical procedure, for example, stereotactic biopsy, within 7 days of first study treatment; placement of a vascular access device, within 2 days of first study treatment
- History of intracranial abscess within 6 months prior to first study treatment
- History of active gastrointestinal bleeding within 6 months prior to first study treatment
- Serious, non-healing wound, active ulcer, or untreated bone fracture
- Known hypersensitivity to any component of bevacizumab or CTO
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: CTO and Bevacizumab (Phase 1)
The combination of CTO with the standard dosing of bevacizumab of 10 mg/kg every 2 weeks among patients with recurrent malignant glioma (World Health Organization (WHO) grade III or IV) that have previously failed bevacizumab
|
Altri nomi:
|
Sperimentale: Phase 2: CTO alone (Phase 2)
The first 25 patients will be treated with CTO alone at the maximum tolerated dose (MTD) established in the Phase 1 portion of the study.
|
Altri nomi:
|
Sperimentale: CTO and Bevacizumab (Phase 2)
The second group of 25 patients will be treated with the combination of CTO at the MTD established in the Phase 1 portion of this study and standard dosing of bevacizumab.
|
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Phase 1: Determine the Maximum Tolerated Dose (MTD) of CTO when combined with standard dosing of bevacizumab
Lasso di tempo: 1 year
|
A standard "3+3" design to determine the MTD of CTO in combination with bevacizumab.
Subjects will be administered CTO orally on a continuous daily dosing schedule, while subjects will receive bevacizumab (10 mg/kg) every 2 weeks.
Cohorts of 3-6 subjects will accrue at each dose level of CTO, beginning with 225 mg/m2, until MTD is defined.
The MTD is the highest dose level at which ≤ 1 out of 6 experienced a dose limiting toxicity (DLT).
|
1 year
|
Phase 2: Percentage of subjects who remain alive and progression-free at 6 months
Lasso di tempo: 2 years
|
Percentage of participants surviving six months from start of study treatment without progression of disease.
Progression-free survival (PFS) was defined as the time from start of study treatment to the date of the first documented progression according to the Response Assessment in Neuro-Oncology (RANO) criteria, or to death due to any cause.
|
2 years
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Fase 2: percentuale di soggetti che manifestano una tossicità dose-limitante (DLT) durante qualsiasi ciclo di trattamento del protocollo
Lasso di tempo: 2 anni
|
Tutte le tossicità saranno raccolte utilizzando Common Terminology Criteria for Adverse Events (CTCAE) versione 4.0. I DLT saranno definiti come uno qualsiasi dei seguenti eventi che sono possibilmente, probabilmente o sicuramente attribuibili a CTO o lomustina: Non ematologico:
Ematologico:
|
2 anni
|
Phase 1: Number of subjects who experience a dose-limiting toxicity (DLT) during cycle 1
Lasso di tempo: 1 year
|
All toxicities will be collected using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. DLTs will be defined as any of the following events that are possibly, probably, or definitely attributable to CTO or lomustine: Non-hematologic:
Hematologic:
|
1 year
|
Phase 2: Median Overall Survival (OS)
Lasso di tempo: 2 years
|
Time in months from start of study treatment to date of death due to any cause.
Patients alive as of the last follow-up will have OS censored at the last follow-up date.
Median OS will be estimated using a Kaplan-Meier curve.
|
2 years
|
Phase 2: 6 and 12 month Overall Survival (OS)
Lasso di tempo: 2 years
|
Percentage of participants surviving 6 and 12 months from start of study treatment.
OS is defined as time from start of study treatment to the date of death due to any cause.
|
2 years
|
Phase 2: Percentage of subjects with best overall response (BOR) of complete response (CR) or partial response (PR)
Lasso di tempo: 2 years
|
Response is based on Response Assessment in Neuro-Oncology (RANO) criteria as determined by investigator assessment.
A confirmation of response was not required.
Complete Response was defined as complete disappearance on MR/CT of all enhancing tumor and mass effect, off all corticosteroids (or receiving only adrenal replacement doses), accompanied by a stable or improving neurologic examination, and maintained for at least 4 weeks.
Partial Response was defined as greater than or equal to 50% reduction in tumor size on MR/CT by bi-dimensional measurement, on a stable or decreasing dose of corticosteroids, accompanied by a stable or improving neurologic examination, and maintained for at least 4 weeks.
|
2 years
|
Phase 2: Median PFS
Lasso di tempo: 2 years
|
Time in months from start of study treatment to the date of first progression according to RANO criteria, or to death due to any cause.
Patients alive who had not progressed as of the last follow-up will have PFS censored at the last follow-up date.
Median PFS will be estimated using a Kaplan-Meier curve.
|
2 years
|
Phase 2: 12 month PFS
Lasso di tempo: 2 years
|
Percentage of participants surviving six months from the start of study treatment without progression of disease.
PFS is defined as the time from the date of study treatment initiation to the date of the first documented progression according to the RANO criteria, or to death due to any cause.
|
2 years
|
Collaboratori e investigatori
Sponsor
Collaboratori
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Neoplasie per tipo istologico
- Neoplasie
- Neoplasie, ghiandolari ed epiteliali
- Neoplasie, Neuroepiteliali
- Tumori neuroectodermici
- Neoplasie, cellule germinali ed embrionali
- Neoplasie, tessuto nervoso
- Glioma
- Effetti fisiologici delle droghe
- Meccanismi molecolari dell'azione farmacologica
- Agenti antineoplastici
- Agenti antineoplastici, immunologici
- Inibitori dell'angiogenesi
- Agenti di modulazione dell'angiogenesi
- Sostanze per la crescita
- Inibitori della crescita
- Modulatori di trasporto a membrana
- Ormoni e agenti regolatori del calcio
- Bloccanti dei canali del calcio
- Bevacizumab
- Carbossiammido-triazolo
Altri numeri di identificazione dello studio
- Pro00044274
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su CTO and Bevacizumab
-
Corindus Inc.TerminatoDisfunsione dell'arteria coronaria | Intervento coronarico percutaneo | Occlusione totale cronica dell'arteria coronariaStati Uniti
-
The First Affiliated Hospital with Nanjing Medical...ReclutamentoOcclusione totale cronica dell'arteria coronariaCina
-
Leif ThuesenReclutamentoArresto cardiaco | Angina pectoris | Occlusione totale cronica dell'arteria coronariaDanimarca
-
SoundBite Medical Solutions, Inc.Completato
-
Universitätsmedizin MannheimIHF GmbH - Institut für Herzinfarktforschung; Herzzentrum LahrNon ancora reclutamentoDisfunsione dell'arteria coronaria | Arresto cardiaco | Occlusione totale cronica
-
Kerckhoff Heart CenterInstitute of Cardiology, Warsaw, Poland; University of Giessen; University Hospital...CompletatoDisfunsione dell'arteria coronariaGermania, Polonia
-
Ureca BVTerminato
-
Yale UniversityBoston Scientific CorporationTerminatoOcclusione totale cronica femoro-poplitea sintomaticaStati Uniti
-
Tactical Therapeutics, Inc.Attivo, non reclutanteTumori solidi, Glioblastoma, Gliomi maligni ricorrentiStati Uniti
-
AngioSafe, Inc.Veranex, Inc.ReclutamentoMalattia arteriosa periferica | Occlusione dell'arteria perifericaStati Uniti